featured
Oral Cladribine Delays Conversion to Clinically Definite Multiple Sclerosis at First Demyelinating Event
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of Oral Cladribine on Time to Conversion to Clinically Definite Multiple Sclerosis in Patients With a First Demyelinating Event (ORACLE MS): A Phase 3 Randomised Trial
Lancet Neurol 2014 Mar 01;13(3)257-267, TP Leist, G Comi, BA Cree, PK Coyle, MS Freedman, HP Hartung, P Vermersch, F Casset-Semanaz, M ScaramozzaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.